Savastano Silvia, Di Somma Carolina, Colao Annamaria, Barrea Luigi, Orio Francesco, Finelli Carmine, Pasanisi Fabrizio, Contaldo Franco, Tarantino Giovanni
Dipartimento di Medicina Clinica e Chirurgia, Università Federico II di Napoli, Italy.
IRCCS SDN, Napoli, Italy.
Growth Horm IGF Res. 2015 Feb;25(1):28-33. doi: 10.1016/j.ghir.2014.10.006. Epub 2014 Oct 28.
The main components of GH/insulin-like growth factor (IGF)-1 axis and Sirtuin 4 (Sirt4), highly expressed in liver and skeletal muscle mitochondria, serve as active regulators of mitochondrial oxidative capacity with opposite functions. In obesity both GH/IGF-1 status and serum Sirt4 levels, likely mirroring its reduced mitochondrial expression, might be altered.
To evaluate the association between circulating levels of Sirt4, body composition, metabolic parameters and cardio-metabolic risk profile in obese patients according to their different GH/IGF-1 status.
Cross-sectional study with measurement of serum Sirt4, GH after GH releasing hormone (GHRH)+Arginine test, IGF-1 and assessment of body composition, glucose and lipid metabolism in 50 class II-III obese subjects (BMI 35.6 to 62.1 kg/m(2)) and 15 normal weight subjects. Low GH secretion and IGF-1 were defined using pre-determined cutoff-points. The Homeostatic Metabolic Assessment of insulin resistance index and Visceral adiposity index were also calculated. The association of Sirt4 with peak stimulated GH and IGF-1, body composition, metabolic parameters and cardio-metabolic risk profile was assessed.
Serum Sirt4 was inversely related to anthropometric and metabolic parameters and positively related to peak GH and IGF-1. After adjusting for peak GH and IGF-1, the relationships between Sirt4 and BMI became not significant. At multiple regression analysis IGF-1 (p<0.001) was the independent predictor for Sirt4.
There was a close relationship between low IGF-1 and low serum Sirt4. This observation suggested that in obese patients, low GH/IGF-1 status was likely associated with a major compensatory decrease in circulating levels of Sirt4 to oppose to its negative regulator effect on mitochondrial oxidative capacity.
生长激素/胰岛素样生长因子(IGF)-1轴的主要成分和沉默调节蛋白4(Sirt4)在肝脏和骨骼肌线粒体中高度表达,作为线粒体氧化能力的活性调节剂,具有相反的功能。在肥胖症中,生长激素/IGF-1状态和血清Sirt4水平可能会发生改变,这可能反映了其线粒体表达的降低。
根据肥胖患者不同的生长激素/IGF-1状态,评估血清Sirt4水平、身体成分、代谢参数和心血管代谢风险谱之间的关联。
横断面研究,对50名II-III级肥胖受试者(体重指数35.6至62.1 kg/m²)和15名正常体重受试者进行血清Sirt4、生长激素释放激素(GHRH)+精氨酸试验后的生长激素、IGF-1测量,并评估身体成分、葡萄糖和脂质代谢。使用预先确定的切点定义低生长激素分泌和IGF-1。还计算了胰岛素抵抗指数的稳态代谢评估和内脏脂肪指数。评估了Sirt4与峰值刺激生长激素和IGF-1、身体成分、代谢参数和心血管代谢风险谱之间的关联。
血清Sirt4与人体测量和代谢参数呈负相关,与峰值生长激素和IGF-1呈正相关。在调整峰值生长激素和IGF-1后,Sirt4与体重指数之间的关系变得不显著。在多元回归分析中,IGF-1(p<0.001)是Sirt4的独立预测因子。
低IGF-1与低血清Sirt4之间存在密切关系。这一观察结果表明,在肥胖患者中,低生长激素/IGF-1状态可能与循环Sirt4水平的主要代偿性降低有关,以对抗其对线粒体氧化能力的负调节作用。